Reviewing Acceleron Pharma Inc. (XLRN)’s and Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB)’s results

Acceleron Pharma Inc. (NASDAQ:XLRN) and Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acceleron Pharma Inc. 13.88M 157.39 112.06M -2.45 0.00
Navidea Biopharmaceuticals Inc 1.45M 22.62 19.16M -0.12 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Acceleron Pharma Inc. and Navidea Biopharmaceuticals Inc.

Profitability

Table 2 provides Acceleron Pharma Inc. and Navidea Biopharmaceuticals Inc’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Acceleron Pharma Inc. -807.35% -32.7% -30.9%
Navidea Biopharmaceuticals Inc -1,321.38% -355.9% -119.6%

Volatility & Risk

Acceleron Pharma Inc.’s current beta is 1.29 and it happens to be 29.00% more volatile than Standard and Poor’s 500. Navidea Biopharmaceuticals Inc’s -0.53 beta is the reason why it is 153.00% less volatile than Standard and Poor’s 500.

Analyst Recommendations

Acceleron Pharma Inc. and Navidea Biopharmaceuticals Inc Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acceleron Pharma Inc. 0 1 1 2.50
Navidea Biopharmaceuticals Inc 0 0 0 0.00

The upside potential is 53.34% for Acceleron Pharma Inc. with consensus target price of $65.

Institutional & Insider Ownership

The shares of both Acceleron Pharma Inc. and Navidea Biopharmaceuticals Inc are owned by institutional investors at 98.1% and 6.6% respectively. About 0.1% of Acceleron Pharma Inc.’s share are held by insiders. Competitively, insiders own roughly 12.4% of Navidea Biopharmaceuticals Inc’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acceleron Pharma Inc. -9.13% -14.31% -6.67% 37.98% 37.04% 13.34%
Navidea Biopharmaceuticals Inc -25.52% -41.38% -14.85% -39.79% -67.26% -59.69%

For the past year Acceleron Pharma Inc. has 13.34% stronger performance while Navidea Biopharmaceuticals Inc has -59.69% weaker performance.

Summary

On 9 of the 11 factors Acceleron Pharma Inc. beats Navidea Biopharmaceuticals Inc.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinsons disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs and therapeutics. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, San Diego. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.